Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, is navigating a critical phase in its development pipeline. With several key ...

To stay up to date on Akari's recent developments on the Webull Corporate Connect Services Platform, current Webull users can ...

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...

Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to I TM), announced ...

A microbioreactor is a way of “doing more with less” succinctly stated Wei-Xiang Sin, PhD, research scientist at SMART CAMP. As these tiny growth machines become even more sophisticated with machine ...

The highly anticipated 3rd edition of Pharma Live Expo & Summit 2025, a premier event for the global pharmaceutical, ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

My patients have shared with me a newfound mistrust over the safety of all vaccines since the Covid vaccine mandates were ...

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of a public offering of an ...

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

Valeria Kogan, PhD, Founder and CEO of Fermata has been recognized as one of Forbes' “30 Under 30” in 2022, Valeria is a serial entrepreneur with a proven track record in biotechnology and innovation.